Skip to main content

Table 1 Geometric means for OPG and TRAIL (in pg/ml) adjusted for age and center by clinical characteristics

From: Postdiagnosis circulating osteoprotegerin and TRAIL concentrations and survival and recurrence after a breast cancer diagnosis: results from the MARIE patient cohort

 

n = 2,456

n (%)

OPG

Geometric mean (95%CI)

pa

n = 2,457

n (%)

TRAIL

Geometric mean (95%CI)

pa

Age at diagnosis (years)b

50–54

55–59

60–64

65–69

70–75

374 (15.2)

499 (20.3)

720 (29.3)

612 (24.9)

251 (10.2)

175.1 (169.1–181.4)

192.6 (186.9–198.6)

204.6 (199.5–209.8)

215.4 (209.6–221.4)

239.0 (229.0–249.5)

 < 0.0001

375 (15.3)

501 (20.4)

719 (29.3)

611 (24.9)

251 (10.2)

18.2 (17.3–19.1)

19.8 (19.0–20.7)

20.4 (19.6–21.1)

20.5 (19.7–21.3)

20.1 (18.9–21.4)

0.003

Stagec

In situ/stage 0

154 (6.5)

203.0 (192.3–214.3)

0.90

154 (6.5)

22.2 (20.5–24.1)

0.01

0-IIIa

2104 (89.0)

203.2 (200.2–206.2)

 

2106 (89.0)

19.8 (19.4–20.2)

 

 ≥ IIIb

107 (4.5)

206.4 (193.4–220.3)

 

106 (4.5)

20.9 (19.0–23.0)

 

Tumor size (cm)c,d

 ≤ 2

1303 (58.9)

201.9 (198.1–205.7)

0.52

1303 (58.9)

19.8 (19.3–20.3)

0.90

 > 2–5

787 (35.6)

206.0 (201.1–211.0)

 

788 (35.6)

20.0 (19.3–20.7)

 

 > 5

77 (3.5)

209.3 (193.9–226.1)

 

77 (3.5)

19.3 (17.2–21.6)

 

Growth into chest wall

44 (2.0)

200.6 (181.2–222.0)

 

44 (2.0)

20.4 (17.6–23.7)

 

Nodal statusc,d

0

1529 (69.2)

202.5 (199.1–206.1)

0.10

1529 (69.1)

20.0 (19.5–20.5)

0.64

1–3

486 (22.0)

202.6 (196.5–208.9)

 

487 (22.0)

19.6 (18.8–20.5)

 

 ≥ 4

196 (8.9)

214.1 (204.0–224.7)

 

196 (8.9)

19.4 (18.1–20.8)

 

Tumor gradec,d

Low/Moderate

1637 (74.0)

202.6 (199.3–206.0)

0.30

1638 (74.1)

20.0 (19.5–20.5)

0.26

High

574 (26.0)

206.2 (200.4–212.1)

 

574 (26.0)

19.5 (18.7–20.3)

 

Hormone receptor statusc,d

ER + PR + 

1535 (69.4)

201.9 (198.5–205.5)

0.09

1536 (69.4)

19.8 (19.3–20.3)

0.49

ER + /PR-/ER-PR + /hormone therapy

367 (16.6)

203.5 (196.5–210.8)

 

367 (16.6)

19.6 (18.6–20.6)

 

ER-PR-

309 (14.0)

211.7 (203.7–219.9)

 

309 (14.0)

20.4 (19.3–21.6)

 

HER2 statusc,d

HER2 + 

440 (21.0)

205.2 (198.7–211.8)

0.70

440 (21.0)

21.2 (20.2–22.2)

0.003

HER2-

1656 (79.0)

203.7 (200.4–207.1)

 

1656 (79.0)

19.6 (19.1–20.1)

 
  1. OPG osteoprotegerin; ER estrogen receptor; n number of observations; p p-value/probability; PR progesterone receptor; TRAIL TNF-related apoptosis-inducing ligand
  2. aCross-sectional associations between clinical characteristics and OPG and TRAIL were evaluated in a linear regression model adjusted for age and center
  3. bAge at diagnosis is adjusted for center only
  4. cAdditionally 91 women had neoadjuvant chemotherapy and no pre-treatment data available
  5. dAdditionally 154 women were diagnosed tumor in situ or stage 0
  6. Missing: HER2 status n = 115 (OPG) n = 116 (TRAIL)